Ascendis Pharma (BMV:ASND N) - Stock Price, News & Analysis

ASND N Stock Overview

A biopharmaceutical company, focuses on developing therapies for unmet medical needs.

ASND N fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Trading at 70.4% below our estimate of its fair value

Earnings are forecast to grow 67.3% per year

Risk Analysis

Negative shareholders equity

Shares are highly illiquid

Has less than 1 year of cash runway

Shareholders have been diluted in the past year

Ascendis Pharma A/S Competitors

Akeso

SEHK:9926

HK$32.7b

Telix Pharmaceuticals

ASX:TLX

AU$6.2b

Global Blood Therapeutics

NasdaqGS:GBT

US$4.6b

Rhythm Pharmaceuticals

NasdaqGM:RYTM

US$2.4b

Price History & Performance

Summary of all time highs, changes and price drops for Ascendis Pharma
Historical stock prices
Current Share Price	US$2,090.00
52 Week High	US$2,115.00
52 Week Low	US$2,090.00
Beta	0.59
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	-5.43%
Change since IPO	205.55%

Recent updates

Shareholder Returns

	ASND N	MX Biotechs	MX Market
7D	0%	0%	0%
1Y	n/a	0%	0%

Return vs Industry: Insufficient data to determine how ASND N performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how ASND N performed against the MX Market.

Price Volatility

Is ASND N's price volatile compared to industry and market?
ASND N volatility
ASND N Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: ASND N has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine ASND N's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2006	879	Jan Mikkelsen	ascendispharma.com

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

Ascendis Pharma A/S Fundamentals Summary

How do Ascendis Pharma's earnings and revenue compare to its market cap?
ASND N fundamental statistics
Market cap	Mex$141.86b
Earnings (TTM)	-Mex$9.82b
Revenue (TTM)	Mex$6.44b

22.0x

P/S Ratio

-14.5x

P/E Ratio

Is ASND N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ASND N income statement (TTM)
Revenue	€329.02m
Cost of Revenue	€47.34m
Gross Profit	€281.68m
Other Expenses	€783.25m
Earnings	-€501.57m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-8.75
Gross Margin	85.61%
Net Profit Margin	-152.44%
Debt/Equity Ratio	-239.8%

How did ASND N perform over the long term?

See historical performance and comparison

ASND N Stock Overview

Rewards

Risk Analysis

Ascendis Pharma A/S Competitors

SEHK:9926

HK$32.7b

ASX:TLX

AU$6.2b

NasdaqGS:GBT

US$4.6b

NasdaqGM:RYTM

US$2.4b

Price History & Performance

Recent News & Updates

Ascendis Pharma A/S Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism

New minor risk - Shareholder dilution

Ascendis Pharma A/S Announces 2-Year Results from A Post-Hoc Analysis of the Company's Phase 3 PaTHway Trial

Ascendis Pharma A/S, Annual General Meeting, May 30, 2024

Ascendis Pharma A/S to Report Q1, 2024 Results on May 02, 2024

Recent updates

Ascendis Pharma A/S Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism

New minor risk - Shareholder dilution

Ascendis Pharma A/S Announces 2-Year Results from A Post-Hoc Analysis of the Company's Phase 3 PaTHway Trial

Ascendis Pharma A/S, Annual General Meeting, May 30, 2024

Ascendis Pharma A/S to Report Q1, 2024 Results on May 02, 2024

Ascendis Pharma A/S Announces United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer

Ascendis Pharma A/S to Report Fiscal Year 2023 Results on Feb 07, 2024

Ascendis Pharma A/S Introduces Vision 2030

New minor risk - Profitability

Ascendis Pharma A/S Announces New Analyses from Blinded and Ongoing Open-Label Extension Portions of ACcomplisH

Ascarma A/S Announces TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency

New major risk - Negative shareholders equity

FDA Accepts for Review Resubmitted NDA for Transcon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism

Ascendis Pharma A/S Announces European Commission Approval of YORVIPATH (Palopegteriparatide) for Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Resubmits NDA for TransCon™? PTH to the U.S. FDA

Ascendis Presents Updated and New Transco Il-2 ß/? Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types At Esmo 2023

Ascendis Pharma A/S Presents Transcon Pth Data At the American Thyroid Association Annual Meeting

Ascendis Pharma A/S Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency

Ascendis Pharma Launches SKYTROFA (Lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency

Ascendis Pharma A/S Receives Positive CHMP Opinion for Transcon PTH (Palopegteriparatide) for Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Announces New Post Hoc Analysis Showing Adults with Hypoparathyroidism Treated with TransCon PTH

Ascendis Pharma A/S to Report Q2, 2023 Results on Sep 05, 2023

Aendis Pharma A/S Reports One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

Ascendis Pharma Showcases its Latest Endocrinology Programs, Data, and Research at ENDO 2023

Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates

Ascendis Pharma A/S, Annual General Meeting, May 30, 2023

Ascendis Pharma A/S to Report Fiscal Year 2022 Results on Feb 16, 2023

Ascendis Pharma A/S Announces U.S. Food & Drug Administration Allows to Initiate an Expanded Access Program for Its Investigational Parathyroid Hormone Replacement Therapy, Transcon PTH

Ascendis Pharma Submits Marketing Authorization Application to the European Medicines Agency for Transcon™ PTH in Adult Patients with Hypoparathyroidism

TransCon CNP Achieves Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years

Dose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022

Third quarter 2022 earnings released: €3.03 loss per share (vs €1.47 loss in 3Q 2021)

Ascendis Pharma A/S Announces FDA Accepts for Priority Review Its NDA for TransCon(TM) PTH in Adult Patients with Hypoparathyroidism

Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for TranscendIT-101, A Phase 1/2 Clinical Trial of TransCon TLR7/8 Agonist in Solid Tumors

Ascendis Pharma A/S Appoints William Carl Fairey Jr. and Siham Imani as Class I Directors

Ascendis Pharma A/S announces new Week 110 data from the Phase 2 PaTH Forward Trial

Ascendis Pharma Submits Transcon™ Pth New Drug Application to the U.S. FDA for Adult Patients with Hypoparathyroidism

Second quarter 2022 earnings released: €1.46 loss per share (vs €2.50 loss in 2Q 2021)